Pharma Predictions for 2021
Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.
Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.
This webinar focuses on the key considerations for transitioning small molecules from preclinical through clinical development.
Summary: Recorded at Manufacturing Chemist Live 2020, this presentation discusses some of the key issues to consider when planning for the scale-up of a small molecule development program.
Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.
Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.